215 related articles for article (PubMed ID: 32148142)
61. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party.
Sweetenham JW; Carella AM; Taghipour G; Cunningham D; Marcus R; Della Volpe A; Linch DC; Schmitz N; Goldstone AH
J Clin Oncol; 1999 Oct; 17(10):3101-9. PubMed ID: 10506605
[TBL] [Abstract][Full Text] [Related]
62. [Fundamental approaches to the treatment of refractory and relapsed Hodgkin lymphoma].
Filatova LV; Tarasenkova AA; Semiglazova TIu; Gershanovich ML
Vopr Onkol; 2012; 58(4):443-53. PubMed ID: 23607197
[No Abstract] [Full Text] [Related]
63. [Novel treatment options in relapsed and refracter Hodgkin lymphomas].
Illés Á; Jóna Á; Simon Z; Udvardy M; Miltényi Z
Orv Hetil; 2015 Nov; 156(45):1824-33. PubMed ID: 26522856
[TBL] [Abstract][Full Text] [Related]
64. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis.
Bröckelmann PJ; Müller H; Gillessen S; Yang X; Koeppel L; Pilz V; Marinello P; Kaskel P; Raut M; Fuchs M; Borchmann P; Engert A; von Tresckow B
Leukemia; 2022 Mar; 36(3):772-780. PubMed ID: 34628472
[TBL] [Abstract][Full Text] [Related]
65. Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy.
Moskowitz AJ; Herrera AF; Beaven AW
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():477-486. PubMed ID: 31099645
[TBL] [Abstract][Full Text] [Related]
66. [Treatment of relapsed Hodgkin lymphoma after autologous stem cell transplantation].
Illés Á; Simon Z; Udvardy M; Magyari F; Jóna Á; Miltényi Z
Orv Hetil; 2017 Aug; 158(34):1338-1345. PubMed ID: 28823212
[TBL] [Abstract][Full Text] [Related]
67. Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma.
Sureda A
Hematol Oncol Clin North Am; 2007 Oct; 21(5):943-60. PubMed ID: 17908630
[TBL] [Abstract][Full Text] [Related]
68. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
69. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.
Adams HJ; Kwee TC
Ann Hematol; 2016 Apr; 95(5):695-706. PubMed ID: 26931115
[TBL] [Abstract][Full Text] [Related]
70. Disease characteristics of diffuse large B-cell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience.
Gaut D; Romero T; Oveisi D; Howell G; Schiller G
Hematol Oncol; 2020 Feb; 38(1):38-50. PubMed ID: 31674036
[TBL] [Abstract][Full Text] [Related]
71. The role of autologous transplantation in Hodgkin lymphoma.
von Tresckow B; Engert A
Curr Hematol Malig Rep; 2011 Sep; 6(3):172-9. PubMed ID: 21567226
[TBL] [Abstract][Full Text] [Related]
72. Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience.
Roerden M; Sökler M; Kanz L; Bethge W; Vogel W; Walz JS
Ann Hematol; 2020 Feb; 99(2):265-276. PubMed ID: 31897675
[TBL] [Abstract][Full Text] [Related]
73. Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options.
David KA; Mauro L; Evens AM
Curr Treat Options Oncol; 2007 Oct; 8(5):352-74. PubMed ID: 18214690
[TBL] [Abstract][Full Text] [Related]
74. Long-term remissions in patients with early relapse of diffuse large B-cell lymphoma following high-dose chemotherapy, autologous stem cell transplantation, and radiotherapy of residual disease.
Metzner B; Welzel J; Müller TH; Casper J; Kimmich C; Petershofen EK; Renzelmann A; Rosien B; Thole R; Voss A; Willborn K; Köhne CH
Strahlenther Onkol; 2022 Jan; 198(1):39-46. PubMed ID: 34735577
[TBL] [Abstract][Full Text] [Related]
75. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
[TBL] [Abstract][Full Text] [Related]
76. Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party-EBMT.
Bento L; Boumendil A; Finel H; Khvedelidze I; Blaise D; Fegueux N; Castagna L; Forcade E; Chevallier P; Mordini N; Brice P; Deconinck E; Gramatzki M; Corradini P; Hunault M; Musso M; Tsoulkani A; Caballero D; Nati S; Montoto S; Sureda A;
Bone Marrow Transplant; 2021 Mar; 56(3):655-663. PubMed ID: 33046830
[TBL] [Abstract][Full Text] [Related]
77. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival.
Sucak GT; Özkurt ZN; Suyani E; Yaşar DG; Akdemir ÖÜ; Aki Z; Yeğin ZA; Yağci M; Kapucu ÖL
Ann Hematol; 2011 Nov; 90(11):1329-36. PubMed ID: 21437590
[TBL] [Abstract][Full Text] [Related]
78. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis.
Rancea M; von Tresckow B; Monsef I; Engert A; Skoetz N
Crit Rev Oncol Hematol; 2014 Oct; 92(1):1-10. PubMed ID: 24855908
[TBL] [Abstract][Full Text] [Related]
79. Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplant.
Goda JS; Massey C; Kuruvilla J; Gospodarowicz MK; Wells W; Hodgson DC; Sun A; Keating A; Crump M; Tsang RW
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e329-35. PubMed ID: 22672755
[TBL] [Abstract][Full Text] [Related]
80. High-dose chemotherapy followed by autologous stem cell transplantation for patients with refractory/relapsed classical Hodgkin lymphoma: a single center experience from China.
Xie Y; Wang X; Leng X; Zheng W; Ping L; Zhang C; Liu W; Deng L; Wu M; Song Y; Zhu J
Ann Hematol; 2020 Mar; 99(3):549-555. PubMed ID: 31980860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
